Saw Palmetto for Benign Prostatic Hyperplasia

Bent, Stephen; Kane, Christopher J.; Shinohara, Katsuto; Neuhaus, John; Hudes, Esther S.; Goldberg, Harley; Avins, Andrew L.

doi:10.1056/nejmoa053085

Cited by 354 publications

(331 citation statements)

References 22 publications

Supporting

Mentioning

273

Contrasting

Unclassified

Order By: Relevance

“…Overall, symptom-scale score results were reported in 21 studies (Mandressi 1983;Champault 1984;Reece Smith 1986;Gabric 1987;Carbin 1990;Descotes 1995;Carraro 1996;Metzker 1996;Braeckman 1997;Sökeland 1997;Bauer 1999;Marks 2000;Gerber 2001;Preuss 2001;Debruyne 2002;Glémain 2002;Willetts 2003;Lopatkin 2005;Bent 2006;Engelmann 2006;Hizli 2007), but only 14 reported the IPSS or AUA validated scores. Results for nocturia were reported in 14 studies (Boccafoschi 1983;Emili 1983;Mandressi 1983;Champault 1984;Cukier 1985;Tasca 1985;Pannunzio 1986;Reece Smith 1986;Carbin 1990;Mattei 1990;Descotes 1995;Carraro 1996;Preuss 2001;Debruyne 2002), but only 11 reported data that permitted pooling.…”

Section: Description Of Studiesmentioning

confidence: 95%

“…Peak urine flow was reported in 25 studies (Boccafoschi 1983;Emili 1983;Champault 1984;Tasca 1985;Pannunzio 1986;Reece Smith 1986;Gabric 1987;Löbelenz 1992;Descotes 1995;Carraro 1996;Metzker 1996;Braeckman 1997;Sökeland 1997;Bauer 1999;Marks 2000;Gerber 2001;Preuss 2001;Debruyne 2002;Glémain 2002;Willetts 2003;Lopatkin 2005;Bent 2006;Engelmann 2006;Shi 2007;Hizli 2007). Data on prostate size were reported in 13 trials (Emili 1983;Pannunzio 1986;Mattei 1990;Roveda 1994;Carraro 1996;Braeckman 1997;Sökeland 1997;Bauer 1999;Marks 2000;Debruyne 2002;Bent 2006;Hizli 2007;Shi 2007). Nine trials reported endpoints (Roveda 1994;Carraro 1996;Sökeland 1997;Braeckman 1997;Braeckman 1997;Mattei 1990;Mattei 1990;Debruyne 2002;Shi 2007;Hizli 2007), one reported mean change (Bent 2006), and two reported per cent change from baseline (Emili 1983;…”

Section: Description Of Studiesmentioning

confidence: 97%

“…Fourteen trials -including eight new trials for this update - (Metzker 1996;Carraro 1996;Sökeland 1997;Bauer 1999;Marks 2000;Gerber 2001;Preuss 2001;Debruyne 2002;Glémain 2002;Lopatkin 2005;Engelmann 2006;Bent 2006;Shi 2007;Hizli 2007) provided efficacy outcomes using validated, self-reporting questionnaires (AUA, IPSS), and which were graded on a 0 ('Never') to 5 ('Almost always') scale, for a total score of 35 points. Of the 30 included trials, 12 used Permixon®, a commercialized extract of the fruit of Serenoa repens.…”

Section: Description Of Studiesmentioning

confidence: 99%

“…Data on prostate size were reported in 13 trials (Emili 1983;Pannunzio 1986;Mattei 1990;Roveda 1994;Carraro 1996;Braeckman 1997;Sökeland 1997;Bauer 1999;Marks 2000;Debruyne 2002;Bent 2006;Hizli 2007;Shi 2007). Nine trials reported endpoints (Roveda 1994;Carraro 1996;Sökeland 1997;Braeckman 1997;Braeckman 1997;Mattei 1990;Mattei 1990;Debruyne 2002;Shi 2007;Hizli 2007), one reported mean change (Bent 2006), and two reported per cent change from baseline (Emili 1983;Pannunzio 1986).…”

Section: Description Of Studiesmentioning

confidence: 99%

“…Serenoa repens alone or in combination versus placebo-There were 21 trials comparing Serenoa repens, alone or in combination, to placebo (Boccafoschi 1983;Emili 1983;Mandressi 1983 (Mandressi was a three-arm trial with placebo and active controls); Champault 1984;Tasca 1985;Cukier 1985;Reece Smith 1986;Gabric 1987;Mattei 1990;Löbelenz 1992;Braeckman 1997;Descotes 1995;Metzker 1996;Bauer 1999;Marks 2000;Preuss 2001;Gerber 2001;Willetts 2003;Lopatkin 2005;Bent 2006;Shi 2007). Eight trials (Metzker 1996;Bauer 1999;Marks 2000;Gerber 2001;Preuss 2001;Lopatkin 2005;Bent 2006;Shi 2007) reported baseline values for IPSS total score for a weighted mean of 16.6 points, indicating moderately severe symptoms.…”

Section: Description Of Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Serenoa repensfor benign prostatic hyperplasia

Tacklind¹,

MacDonald

Rutks

et al. 2012

Cochrane Database of Systematic Reviews

107

104

View full text Add to dashboard Cite

Section: Description Of Studiesmentioning

confidence: 95%

Section: Description Of Studiesmentioning

confidence: 97%

Section: Description Of Studiesmentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Serenoa repensfor benign prostatic hyperplasia

Tacklind¹,

MacDonald

Rutks

et al. 2012

Cochrane Database of Systematic Reviews

107

104

View full text Add to dashboard Cite

Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms

Barry

Meleth

Lee

et al. 2011

JAMA

158

118

View full text Add to dashboard Cite

Context Saw palmetto fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prostatic hyperplasia. However, recent clinical trials have questioned their efficacy, at least at standard doses (320 mg daily). Objective To determine the effect of a saw palmetto extract at up to three times the standard dose on lower urinary tract symptoms attributed to benign prostatic hyperplasia. Design Multicenter placebo-controlled randomized trial conducted from June, 2008 through October, 2010. Setting Eleven North American clinical sites. Participants Were men at least 45 years old, with a peak urinary flow rate ≥ 4 ml/sec, an AUA Symptom Index (AUASI) score ≥ 8 and ≤ 24, and no exclusions. Interventions One, two, and then three 320 mg daily doses of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks. Main Outcome Measures Primary outcome was the difference in AUASI score from baseline to 72 weeks. Secondary outcomes were measures of urinary bother; nocturia; uroflow; postvoid residual; prostate-specific antigen; participants’ global assessments; and indices of sexual function, continence, sleep quality, and prostatitis symptoms. Results From baseline to 72 weeks, mean AUASI scores decreased from 14.4 to 12.2 points with saw palmetto and from 14.7 to 11.7 points with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto and placebo groups was 0.79 points favoring placebo (bound of the 95% confidence interval most favorable to saw palmetto was 1.77 points, one-sided P=0.91). Saw palmetto was no more effective than placebo for any secondary outcome. No attributable side effects were identified. Conclusions Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo. (CAMUS study number NCT00603304 http://www.ClinicalTrials.gov)

show abstract

Serenoa repensfor benign prostatic hyperplasia

Tacklind¹,

MacDonald²,

Rutks³

et al. 2009

Cochrane Database of Systematic Reviews

101

View full text Add to dashboard Cite

Background-Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (also known by its botanical name of Sabal serrulatum), is one of several phytotherapeutic agents available for the treatment of BPH.Objectives-This systematic review aimed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH.Search strategy-Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, and The Cochrane Library), by checking bibliographies, and by handsearching the relevant literature.Selection criteria-Trials were eligible if they (1) randomized men with symptomatic BPH to receive preparations of Serenoa repens (alone or in combination) for at least four weeks in comparison with placebo or other interventions, and (2) included clinical outcomes such as urologic symptom scales, symptoms, and urodynamic measurements. Eligibility was assessed by at least two independent observers. Data collection and analysis-Information on patients, interventions, and outcomes was extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of Serenoa repens with placebo or other interventions was the change in urologic symptom-scale scores. Secondary outcomes included changes in nocturia and urodynamic measures. The main outcome measure for side effects or adverse events was the number of men reporting side effects.Main results-In this update 9 new trials involving 2053 additional men (a 64.8% increase) have been included. For the main comparison -Serenoa repens versus placebo -3 trials were added with 419 subjects and 3 endpoints (IPSS, peak urine flow, prostate size). Overall, 5222 subjects from 30 randomized trials lasting from 4 to 60 weeks were assessed. Twenty-six trials were double blinded and treatment allocation concealment was adequate in eighteen studies.

show abstract

Saw Palmetto for Benign Prostatic Hyperplasia

Cited by 354 publications

References 22 publications

Serenoa repensfor benign prostatic hyperplasia

Serenoa repensfor benign prostatic hyperplasia

Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms

Serenoa repensfor benign prostatic hyperplasia

Contact Info

Product

Resources

About